The word on The Street in general, suggests a Moderate Buy analyst consensus rating for B2Gold with a $5.08 average price target, a 38.80% upside from current levels. In a report released yesterday, ...

Amdocs delivered quarterly results that met Wall Street’s revenue expectations and modestly surpassed profit forecasts, ...

Equity Residential (NYSE:EQR) is one of the most undervalued stocks. On June 5, Stifel maintained a Buy rating on EQR with a ...

Gaming and Leisure Properties, Inc. (NASDAQ:GLPI) is one of the most undervalued stocks. On June 5, Stifel analysts ...

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is among the best growth stocks to invest in for the next 5 years. Analysts at ...

Churchill Downs Incorporated (NASDAQ:CHDN) ranks among the 30 stocks expected to beat the market by 20 percentage points this ...

According to Benzinga Pro, Stifel Financial's peer group average for short interest as a percentage of float is 3.25%, which ...

The pivotal trial for Neurogene's Rett syndrome gene therapy makes use of baseline controls and a rigorous endpoint that ...

Oracle announced a new cloud agreement, and a Stifel analyst is freshly optimistic about the revenue opportunities ahead of ...

Shares of Dyne Therapeutics declined after the company commenced an underwritten public offering and said it had secured up to $275 million of debt financing. The stock fell 9.8% to $8.59 on Monday.

The company's share price was up 4.6% as of 1:40 p.m. ET, amid a 0.2% gain for the S&P 500 (SNPINDEX: ^GSPC) and a 0.1% gain ...